FDA Approves Opzulera for At-Home Therapy for Skin Repigmentation: What this Means for Melanoma Patients with Vitiligo
On July 18th, the U.S. Food & Drug Administration (FDA) approved the first topically-applied treatment for skin repigmentation for patients with vitiligo after strong results from two Phase 3 trials. Vitiligo, a chronic skin disease, affects 3 in 100 people who have melanoma, categorized as melanoma-associated vitiligo. The approval invites patients with vitiligo, including those with melanoma, to talk with their providers on how Opzelura can serve their skin needs.
Music vs. Melanoma: 13-Year-Old Raises $6K for Research
By Renee Orcione, MRA Development Associate | 7 October 2022
Cassidy Battin, an 8th grader from Carlsbad, California, and her family are no strangers to melanoma. Her great aunt sadly died of uveal melanoma, a rare subtype that forms in the eye, when Cassidy was younger. Her grandfather also had melanoma, along with several other loved ones in the family.
Fish & Melanoma: What’s the Connection?
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 4 October 2022 In News
A study led by researchers at Brown University surprisingly found that people who ate the most fish were the most likely to develop melanoma. Before you change your diet, read more about the study, its findings, and limitations.
Mollie’s Fund Partners to Prevent Skin Cancers Among Firefighters
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 8 September 2022 In Prevention
Every day firefighters put their own safety on the line to protect the lives and property of others. It’s a tough job that puts those who do it at increased risk for burns, smoke inhalation, and other injuries.
Overcoming Melanoma Treatment Resistance Research Update
About half of all patients given cancer immunotherapies do not respond to them, and although targeted therapies often dramatically shrink tumors in most patients, in about three-quarters of those patients, the treatments stop being effective weeks to months after initially killing tumor cells.
Improving AI Performance for People of Color: Diagnosing Melanoma & Other Skin Cancers
The problem with the current state-of-the-art AI and image-based algorithms is that they have been developed using images of moles from light skinned (white) individuals. As a result, existing AI tools are not sensitive enough in people with darker skin. Dr. Albert Chiou, Clinical Associate Professor of Dermatology at Stanford University, the junior faculty member on the L’Oréal Dermatological Beauty Brands-MRA Team Science Award, and his colleagues are working to fix these shortcomings.
MRA's Latest Research Report: The Melanoma Research Community Reunites
Each year, MRA brings together hundreds of people from across the melanoma research community to exchange ideas, report on scientific progress, celebrate achievements, and mourn our collective losses.
Melanoma Clinical Trial Success Story: From Patient Volunteer to No Evidence of Disease
This Mom of three enrolled in a neoadjuvant clinical trial for Stage 3 melanoma. After two infusions of Opdualag, Shannon underwent a successful surgery where doctors removed all affected lymph nodes and tested them, revealing No Evidence of Disease (NED).
What Uveal Melanoma Patients Need to Know about KIMMTRAK
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 18 July 2022 In Science, Treatment
You may have heard of KIMMTRAK, a new therapy that recently earned FDA approval for the treatment of metastatic or unresectable uveal melanoma. Uveal melanoma, also called ocular melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. KIMMTRAK is the first drug to earn FDA approval to treat these patients.
New Funding Alert: Department of Defense Melanoma Research Program
Research Funding Alert: The Department of Defense Melanoma Research Program will award up to $40 million in funding for melanoma research in FY22. Learn more about funding mechanisms, focus area, and deadlines!